06160

230.8004.86%
WL

Wang Lai

President and Global Head of Research & Development

Mr. Lai Wang, PhD., has been Global Head of Research & Development at BeOne Medicines AG since April 01, 2021 and serves as its President since January 1, 2026. Mr. Wang was Senior Vice President and Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development at BeiGene, Ltd until April 1, 2021. He was Senior Vice President and Head of China Development at BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) since January 2018. Mr. Wang is a Research Scientist with the Howard Hughes Medical Institute. Mr. Wang served as Head of Discovery Biomarkers & In Vivo Pharmacology at BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) since May 2011 and its Senior Vice President since September 23, 2016. He joined the BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) in May 2011. Mr. Wang served as the Director of Research at Joyant Pharmaceuticals, where he led a multidisciplinary team that delivered clinical candidates for two novel small-molecule inhibitor oncology programs. Mr. Wang is a insightful Biologist who has discovered a novel apoptosis pathway triggered by a small molecule anti-cancer drug utilizing downstream signaling of TNF-alpha. He received his Ph.D. in 2001 from the University of Texas Health Science Center at San Antonio and his B.S. from Fudan University in 1996.

Positions